Company: NCEL
Filing Date: 2025-11-06
Form Type: POS AM
Source: 0001213900-25-106799
Chunk: 38

Company: NewcelX Ltd.
Filing Date: 2025-11-06
Form: POS AM
Chunk 38
---
 Weighted average common shares used in computing basic and diluted net loss per common share                  |     |                                               |  4,193,689 | -ii            |     |   |  1,543,283 | -i          |     |   | 3,653,424 | -iii  |     |           |     |   |  5,196,708 |   |

____________ (i)This gives effect to the reverse stock split of 1 -for-40as of September 27, 2024. (ii)Adjusted retroactively due to (A) the rights issue under the shelf offering by way of rights published by NLS in 2022 in such a way that each shareholder who held 100 Shares would be entitled to purchase 1 rights unit, with 1 rights unit consisted of 32 Shares, and the total price of each rights unit was USD $10 and the total number of rights units offered was up to 14,623,392 rights units, and (B) the reverse share split conducted by Kadimastem in March 2024, at a 10 -for-1ratio. (iii)This gives effect to the reverse stock split of 1 -for-10as of October 30, 2025. The accompanying notes are an integral part of these unaudited pro forma condensed combined financial statements.

25 Kadimastem Ltd. & NLS Pharmaceutics Ltd.
Notes to accompanying Unaudited Pro Forma Condensed Combined Financial Statements 1.Description of the Proposed Transaction and Basis of Presentation NLS, a biopharmaceutical company, and Kadimastem, a clinical -stagecell therapy company developing and manufacturing “off -the-shelf” allogeneic cell products for the treatment of neurodegenerative diseases and potential cure of diabetes, announced on November 4, 2024 that they have entered into the Merger Agreement to combine the two companies to focus on advancing NLS’s promising, first -inclass Dual Orexin Agonist platform, or DOXA, and Kadimastem’s allogenic cell therapy program with its clinical assets (mainly targeting diabetes and amyotrophic lateral sclerosis (ALS), with Phase 2a studies that are planned to be initiated in the U.S. following the closing of the transaction). AstroRx ®Phase 2a study cost estimation is about $12 million. The necessary steps for study initiation include completion of AstroRx ®clinical production by contract